Leap Therapeutics Files 8-K
Ticker: CYPH · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
LEAP filed an 8-K, likely routine docs. No major news yet.
AI Summary
On October 20, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, formerly Dekkun Corp, is incorporated in Delaware and headquartered in Cambridge, MA.
Why It Matters
This 8-K filing indicates Leap Therapeutics is submitting required documentation to the SEC, which could include updates on financial status or other corporate events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without detailing specific material events, suggesting it's likely procedural.
Key Players & Entities
- Leap Therapeutics, Inc. (company) — Registrant
- Dekkun Corp (company) — Former company name
- October 20, 2025 (date) — Date of earliest event reported
- 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141 (address) — Principal Executive Office
- 617-714-0360 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Leap Therapeutics, Inc. in this 8-K filing?
The provided text for the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
Filing 'Financial Statements and Exhibits' typically means the company is providing updated financial information or accompanying documents as required by the SEC.
When was Leap Therapeutics, Inc. formerly known as Dekkun Corp?
The date of the name change from Dekkun Corp to Leap Therapeutics, Inc. was January 7, 2011.
What is Leap Therapeutics, Inc.'s principal executive office address?
Leap Therapeutics, Inc.'s principal executive office is located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
What is the SIC code for Leap Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Leap Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-10-20 08:49:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share LPTX The NASDAQ Capital M
Filing Documents
- tm2529085d1_8k.htm (8-K) — 24KB
- tm2529085d1_ex99-1.htm (EX-99.1) — 19KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001104659-25-100646.txt ( ) — 217KB
- lptx-20251020.xsd (EX-101.SCH) — 3KB
- lptx-20251020_lab.xml (EX-101.LAB) — 33KB
- lptx-20251020_pre.xml (EX-101.PRE) — 22KB
- tm2529085d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 20, 2025, Leap Therapeutics, Inc. (the "Company") issued a press release announcing final results from Part B of its DeFianCe study. The final clinical results were presented on behalf of the DeFianCe study investigators by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA in a Mini Oral session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. A copy of the news release is filed with this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 8.01 by reference. 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Date: October 20, 2025 /s/ Douglas E. Onsi Douglas E. Onsi President & CEO